TITLE:
Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience
AUTHORS:
Juan C. Fernandez-Guerrero, Juan A. Herrador, Manuel Guzman, Victor Aragon, Carmen Adamuz
KEYWORDS:
Percutaneous Coronary Interventions; “Off Label” Lesions; Prognosis
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.3 No.2,
April
25,
2013
ABSTRACT: Objectives: We sought to evaluate the efficacy and
safety of unrestricted implantation of everolimus eluting stent Xience V
(EES-XV) in a cohort of real- world patients with unprotected left main
coronary disease (ULMCD). Background: The second-generation EES-XV stent is
currently one of the most commonly used drug-eluting stents in clinical
practice. It has been shown to be superior to paclitaxel-eluting stents, but
its relative merits on unprotected left main coronary disease have been less
extensively assessed. Methods: Between 2007
and 2010, in this single-center registry, we evaluated the clinical
outcomes of 98 patients with ULMCD who underwent percutaneous coronary
intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At
25.63 ± 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse
coronary event (MACE), death from cardiovascular disease (n = 6; 6.1%) and
target lesion revascularization (TLR; n = 7; 7.1%). The predictors of death
from cardiovascular disease were: previous PCI and left ventricular
dysfunction. The only predictor of TLR was the placement of 2 stents in the
left main coronary artery. Conclusions: In this single- center real-world
registry, we found that elective ULMCD stenting with EES-XV provided good
short-, medium- and long-term outcomes, with an estimated cumulative need for
TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2
years.